PIIND2026-07-012026-09-30PIIND2026-09-30PIIND2026-03-31PIIND2026-04-012026-09-30PIIND2026-07-012026-09-30in-capmkt:OtherExpenses1MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses2MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses3MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses4MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses5MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses6MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses7MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses8MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses9MemberPIIND2026-07-012026-09-30in-capmkt:OtherExpenses10MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses1MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses2MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses3MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses4MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses5MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses6MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses7MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses8MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses9MemberPIIND2026-04-012026-09-30in-capmkt:OtherExpenses10MemberPIIND2026-09-30OtherNoncurrentFinancialAssetsDomain1PIIND2026-09-30OtherNoncurrentAssetsDomain1PIIND2026-09-30OtherCurrentFinancialAssetsDomain1PIIND2026-09-30OtherCurrentAssetsDomain1PIIND2026-09-30OtherNoncurrentFinancialLiabilitiesDomain1PIIND2026-09-30OtherNoncurrentFinancialLiabilitiesDomain2PIIND2026-09-30OtherCurrentFinancialLiabilitiesDomain1PIIND2026-09-30OtherCurrentFinancialLiabilitiesDomain2PIIND2026-09-30OtherCurrentLiabilitiesDomain1PIIND2026-07-012026-09-30in-capmkt:ReportableSegments1MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments2MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments3MemberPIIND2026-04-012026-09-30in-capmkt:ReportableSegments1MemberPIIND2026-04-012026-09-30in-capmkt:ReportableSegments2MemberPIIND2026-04-012026-09-30in-capmkt:ReportableSegments3MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments1MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments2MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments3MemberPIIND2026-04-012026-09-30in-capmkt:ReportableSegments1MemberPIIND2026-04-012026-09-30in-capmkt:ReportableSegments2MemberPIIND2026-04-012026-09-30in-capmkt:ReportableSegments3MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments1MemberPIIND2026-09-30in-capmkt:ReportableSegments1MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments2MemberPIIND2026-09-30in-capmkt:ReportableSegments2MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments3MemberPIIND2026-09-30in-capmkt:ReportableSegments3MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments1MemberPIIND2026-09-30in-capmkt:ReportableSegments1MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments2MemberPIIND2026-09-30in-capmkt:ReportableSegments2MemberPIIND2026-07-012026-09-30in-capmkt:ReportableSegments3MemberPIIND2026-09-30in-capmkt:ReportableSegments3MemberPIIND2026-07-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1PIIND2026-04-012026-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1PIIND2026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1PIIND2026-07-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss2PIIND2026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss1PIIND2026-04-012026-09-30ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares523642PIINDNOTLISTEDINE603J01030PI INDUSTRIES LIMITEDMain BoardEquity2026-04-012027-03-312026-11-042026-10-27INRMillionsQuarterlySecond quarterMulti segment2026-11-0414:00:002026-11-0419:00:00trueCash Flow IndirectNot applicable2026-07-012026-09-30UnauditedConsolidated17018000000611000000176290000007897000000749000000-4600000025650000008400000010490000003526000000158240000001805000000018050000004540000001640000006180000000118700000000035000000122200000016700000013890000001389000000015200000018.058.05008.058.05Notes: <br /> <br /> 1 The above consolidated unaudited financial results were reviewed and recommended by the Audit Committee of the Company and approved by the Board of Directors at their meeting held on November 04, 2026. <br /> <br /> 2 The consolidated financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. <br /> <br /> 3 The consolidated financial results include the results of the following entities namely, Parent Company - PI Industries Limited; Subsidiaries (including step down subsidiaries): (a) PI Health Sciences Limited (b) PI Health Sciences USA, LLC (c) PI Health Sciences Netherlands BV (d) Archimica S.p.A Italy (e) PI AgSciences Limited (Formerly known as Plant Health Care limited) (f) PI AgSciences, Inc. (Formerly known as Plant Health Care, Inc, Nevada) (g) PI AgSciencies, S. de R.L. de C.V. (Formerly known as Plant Health Care de Mexico S. de R.L. de C.V.) (h) PI AgSciences (UK) Limited (Formerly known as Plant Health Care (UK) Limited) (i) PI AgSciences Spain, S.A (Formerly known as Plant Health Care España) (j) PI AgSciences Brasil Ltda (Formerly know as Plant Health Care Insumos Agricolas LTDA) (k) Jivagro Limited (l) PI Life Science Research Limited (m) PI Flowtech B.V. (n) PI Industries Management Consultancies LLC Dubai (o) PI Innoventures Limited (Formerly known as PILL Finance and Investments Limited) (p) PI Japan Co. Limited (q) PI Bioferma Private Limited (r) PI Fermachem Private Limited ; Controlled trust - PII ESOP Trust; Joint Venture - PI Kumiai Private Limited (including its subsidiary - Kumiai Chemical Industry (India) Private Limited (w.e.f July 03, 2026)) ; Associate - Solinnos Agro Sciences Private Limited. <br /> <br /> <br /> 4 "a) In April 2023, PI Health Sciences Limited (PIHS), a wholly owned subsidiary of the Company acquired 100% equity of Solis Pharmachem Private Limited and Therachem Research Medilab (India) Private Limited and specific assets of Therachem Research Medilab LLC, USA. The purchase consideration for the above included contingent consideration to be paid over a period of 6 years subject to achievement of specified business performance and to support for business development activities. <br /> <br /> Considering the performance of the acquired business since the acquisition, and the successful establishment of an experienced in-house global business development team, no longer requiring external business development support, the Company renegotiated a mutually beneficial one-time settlement payment with erstwhile owners. This settlement resulted in a write-back of the contingent consideration of Rs. 1,260 million, which was presented under ""Exceptional Items"" during the year ended March 31, 2026. <br /> <br /> b) Pursuant to the notification of the 'New Labour Codes' as issued in November 2025, the Group reassessed its employee benefit obligations in accordance with the revised definition of wages and accordingly, an incremental liability of Rs. 229 million had been disclosed as an ""Exceptional Item"" during the year ended March 31, 2026." <br /> 5 Segment information as per Ind AS 108 "Operating Segments" is as per Annexure I. <br /> <br /> <br /> <br /> Place: Mumbai For PI Industries Limited <br /> Date: November 04, 2026 <br /> <br /> <br /> <br /> <br /> Regd. Office: Udaisagar Road, Udaipur - 313001 (Raj) Mayank Singhal <br /> Phone: 0294 2492451-55 Fax: 0294 2491946 Vice Chairperson & Managing Director <br /> CIN: L24211RJ1946PLC000469 DIN: 00006651 <br /> 2026-04-012026-09-30UnauditedConsolidated3404100000012520000003529300000014716000000117200000077000000517300000016300000020860000006902000000302890000005004000000050040000001184000000210000000139400000003610000000000540000003664000000487000000415100000041510000000152000000124.1524.150024.1524.15Net impairment losses on financial assets64000000Power, Fuel & Water915000000Environment & Pollution Control Expenses285000000Freight & Cartage229000000Advertisement & Sales Promotion287000000Travelling and Conveyance286000000Legal & professional fees259000000Repairs & Maintenance373000000Laboratory & Testing Charges137000000Other expenses691000000Net impairment losses on financial assets116000000Power, Fuel & Water1714000000Environment & Pollution Control Expenses551000000Freight & Cartage375000000Advertisement & Sales Promotion523000000Travelling and Conveyance599000000Legal & professional fees546000000Repairs & Maintenance729000000Laboratory & Testing Charges294000000Other expenses145500000037565000000998700000006067000000375600000027700000000369000000632000000002340000008660000002930000009410000006261400000012235000000202680000002176300000032940000001391600000090000002200000005947000000015700000041820000007604400000000138658000000152000000114422000000114574000000011457400000013790000000001695000000307400000032300000095600000004353000000696000000737000000106130000001135000000058280000001787400000010610000004240000003720000000197310000000024084000000138658000000Other Financial Assets234000000Other non-current assets941000000Other current financial assets220000000Other current assets4182000000Lease liabilities690000000Other financial liabilities1005000000Lease liabilities231000000Other current financial liabilities5597000000Other current liabilities1061000000Agro Chemicals16280000000Pharma759000000Inter Segment adjustment0Agro Chemicals32768000000Pharma1301000000Inter Segment adjustment0170390000003406900000021000000280000001701800000034041000000Agro Chemicals2473000000Pharma-601000000Inter Segment adjustment-32000000Agro Chemicals6308000000Pharma-1417000000Inter Segment adjustment16700000018400000005058000000000018400000005058000000Agro Chemicals124244000000Pharma14414000000Inter Segment adjustment01386580000000138658000000Agro Chemicals20648000000Pharma3436000000Inter Segment adjustment024084000000024084000000Note: The business of the group is divided into two segments as below: <br /> a) Agro chemicals - Agro chemicals includes Agchem export (CSM), Domestic Agri Brands and Biologicals. <br /> b) Pharma - Pharma comprises contract research and development, contract development and manufacturing of active, key starting materials and intermediates used in pharmaceutical industry.163000000-4100000010960000000-65000000-57000000-6000000195000000014950000000790000000208600000000190000006830000002000000016400000008180000000-37800000007000000015100000004793000000979700000000089800000008899000000000000002900000065520000000000000000000000008180000000-383000000-608800000000000000542000000992000000175000000151700000016300000000-2305000000506000000-4500000046100000028330000003294000000Remeasurements gain/(loss) on defined benefits plans2000000020000000Remeasurements gain/(loss) on defined benefits plans2900000029000000500000010000000Effective portion of gain/(loss) on cash flow hedges69000000Exchange difference on translation of foreign operations106000000175000000Effective portion of gain/(loss) on cash flow hedges640000000Exchange difference on translation of foreign operations5100000069100000023000000223000000167000000487000000